Biologic Enhancement of Wound Healing

Clinics in Plastic Surgery

Volumn 34, Issue 4, 2007, Pages 659-671

  Leahy, Paul J ^a   Lawrence, W Thomas ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BECAPLERMIN; COLONY STIMULATING FACTOR; CT 102; EPIDERMAL GROWTH FACTOR; EYE DROPS; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; ICOSANOID; INTERLEUKIN 1; INTERLEUKIN 1BETA; LEUKOTRIENE DERIVATIVE; NITRIC OXIDE; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED WOUND HEALING FACTOR; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E1; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT FIBROBLAST GROWTH FACTOR 2; RECOMBINANT INTERLEUKIN 1BETA; SOMATOMEDIN; SULFADIAZINE SILVER; THROMBOXANE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA3; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEBRIDEMENT; DECUBITUS; DIABETIC FOOT; HUMAN; KELOID; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; ULCER; WOUND; WOUND CARE; WOUND HEALING;

BIOLOGICAL FACTORS; BIOLOGICAL PRODUCTS; EICOSANOIDS; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTORS; HUMANS; INTERLEUKIN-1; NITRIC OXIDE; SOMATOMEDINS; TRANSFORMING GROWTH FACTOR BETA; WOUND HEALING; WOUNDS AND INJURIES;

EID: 35448947487     PISSN: 00941298     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cps.2007.07.001     Document Type: Review

References (75)

1. Broughton G., Janis J.E., and Attinger C.E. The basic science of wound healing. Plast Reconstr Surg 117 (2006) 12S-34S
2. Lorenz H.P., and Longaker M.T. Wound healing: repair biology and wound and scar treatment. In: Mathes S.J. (Ed). Plastic surgery. 2nd edition (2006), Saunders, Philadelphia 209-234
3. Bennett S.A., and Birnboim H.C. Receptor-mediated and protein kinase-dependent growth enhancement of primary human fibroblasts by platelet activating factor. Mol Carcinog 20 4 (1997) 366-375
4. Cross K., and Mustoe T. Growth factors in wound healing. Surg Clin North Am 83 3 (2003) 531-545
5. 1). Dermatol Surg 30 (2006) 1113-1117
6. Milio G., Mina C., Cospite V., et al. Efficacy of the treatment with prostaglandin E-1 in venous ulcers of the lower limbs. J Vasc Surg 42 (2005) 304-308
7. 1 on flap survival after nicotine application in rats. Ann Plast Surg 55 (2005) 202-206
8. Al-Attar A., Mess S., Thoamassen J.M., et al. Keloid pathogenesis and treatment. Plast Reconstr Surg 117 (2006) 286-300
9. Robson M.C., Abdallah A., Burns B.F., et al. Safety and effect of topical recombinant human interleukin-1beta in the management of pressure sores. Wound Repair Regen 2 (1994) 177-181
10. Holt D.R., Hurson M., Kirk S.J., et al. Recombinant IL-1beta enhances human wound epithelialization. Surg Forum 42 (1991) 3-4
11. DaCosta R.M., Jesus F.M.R., Ancieto C., et al. Randomized double-blind placebo-controlled, dose ranging study of granulocyte-macrophage colony simulating factor in patients with chronic venous ulcers. Wound Repair Regen 7 (1999) 17-25
12. Malik I.A., Zahid M., Haq S., et al. Effect of subcutaneous injection of granulocyte-macrophage colony stimulating factor (GM-CSF) on healing of chronic refractory wounds. Eur J Surg 164 (1998) 747-4
13. Jaschke E., Zabernigg A., and Gattringer C. Recombinant human granulocyte-macrophage colony-stimulating factor applied locally in low doses enhances healing and prevents recurrence of chronic venous ulcers. Int J Dermatol 38 (1999) 380-386
14. Cianfarani F., Tommasi R., Faillia C.M., et al. Granulocyte/macrophage colony-stimulating factor treatment of human chronic ulcers promotes angiogenesis associated with de novo vascular endothelial growth factor transcription in the ulcer bed. Br J Dermatol 154 (2006) 34-41
15. Cruciani M., Lipsky B.A., Mengoli C., et al. Are granulocyte colony-stimulating factors beneficial in treating diabetic foot infections?. Diabetes Care 28 (2005) 454-460
16. Streit M., Beleznay Z., and Braathen L.R. Topical application of tumor necrosis factor-alpha antibody infliximab improves healing of chronic wounds. Int Wound J 3 (2006) 171-179
17. Kirk S.J., Hurson M., Regan M.C., et al. Arginine stimulates wound healing and immune function in elderly human beings. Surgery 114 2 (1993) 155-159
18. de Luis D.A., Izaola O., Cuellar L., et al. Randomized clinical trial with an enteral arginine-enhanced formula in early postsurgical head and neck cancer patients. Eur J Clin Nutr 58 11 (2004) 1505-1508
19. Langkamp-Henken B., Herrlinger-Garcia K.A., Stechmiller J.K., et al. Arginine supplementation is well tolerated but does not enhance mitogen-induced lymphocyte proliferation in elderly nursing home residents with pressure ulcers. JPEN J Parenter Enteral Nutr 24 (2000) 280-287
20. Broughton G., Janis J.E., and Attinger C.E. A brief history of wound care. Plast Reconstr Surg 117 (2006) 6S-11S
21. Cohen S. Isolation of mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biolumin Chemilumin 237 (1962) 1555-1562
22. Nanney L.B. Epidermal and dermal effect of epidermal growth factor during wound repair. J Invest Dermatol 94 (1990) 624-629
23. Cohen I.K., Crossland M.C., Garrett A., et al. Topical application of epidermal growth factor onto partial-thickness wounds in human volunteers does not enhance reepithelialization. Plast Reconstr Surg 96 (1995) 251-254
24. Brown G.L., Nanney L.B., and Griffin J. Enhancement of wound healing by topical treatment with epidermal growth factor. N Engl J Med 321 (1989) 76-79
25. Brown G.L., Curtsinger L., Jurkiewicz M.D., et al. Stimulation of healing chronic wounds by epidermal growth factor. Plast Reconstr Surg 88 (1991) 189-196
26. Pastor J.C., and Calonge M. Epidermal growth factor and corneal wound healing. A multi center study. Cornea 11 (1992) 311-314
27. Falanga V., Eaglstein W.H., Bucalo B., et al. Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers. J Dermatol Surg Oncol 18 (1992) 604-606
28. Tsang M.W., Wong W.K.R., Hung C.S., et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care 26 (2003) 1856-1861
29. Hong J.P., Jung H.D., and Kim Y.W. Recombinant human epidermal growth factor (EGF) to enhance healing for diabetic foot ulcers. Ann Plast Surg 56 (2006) 394-398
30. Schultz G., Rotatori D.S., and Clark W. EGF and TGF alpha in wound healing and repair. J Cell Biochem 45 (1991) 346-352
31. Schmid C. Insulin-like growth factors. Cell Biol Int 19 (1995) 445-458
32. Cromack D.T., Pierce G.F., and Mustoe T.A. TGF-beta and PDGF mediated tissue repair: identifying mechanisms of action using impaired and normal models of wound healing. Prog Clin Biol Res 365 (1991) 359-373
33. Mustoe T.A., Pierce G.F., Thomson A., et al. Accelerated healing of incisional wounds in rats induced by transforming growth factor-beta. Science 237 (1987) 1333-1335
34. Lawrence W.T., Norton J.A., Sporn M.B., et al. The reversal of an Adriamycin induced healing impairment with chemoattractants and growth factors. Ann Surg 203 (1986) 142-147
35. Robson M.C., Phillip L.G., Cooper D.M., et al. Safety and effect of transforming growth factor-beta(2) for the treatment of venous stasis ulcers. Wound Repair Regen 3 (1995) 157-167
36. Robson M.C., Steed D.L., McPherson J.M., et al. Use of transforming growth factor beta2 (TGF-beta2) in treatment of chronic foot ulcers in diabetic patients. [abstract]. Wound Repair Regen 7 (1999) A266
37. Hirshberg J., Coleman J., Marchant B., et al. TGF-beta3 in the treatment of pressure ulcers: a preliminary report. Adv Skin Wound Care 14 (2001) 91-95
38. Urist M.R. Bone: formation by autoinduction. Science 150 (1965) 893-899
39. Wozney J.M., Rosen V., Celeste A.J., et al. Novel regulators of bone formation: molecular clones and activities. Science 242 (1988) 1528-1534
40. Cheng H., Jiang W., Phillips F.M., et al. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg Am 85 (2003) 1544-1552
41. Riedel G.E., and Valentin-Opran A. Clinical evaluation of rhBMP-2/ACS in orthopedic trauma: a progress report. Orthopedics 22 (1999) 663-665
42. Burkus J.K., Transfeldt E.E., Kitchel S.H., et al. Clinical and radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2. Spine 27 (2002) 2396-2408
43. Govender S., Csimma C., Genant H.K., et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 84A (2002) 2123-2134
44. Friedlaender G.E., Perry C.R., Cole J.D., et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 83A Suppl 1 (2001) 151-158
45. Robson M.C., Phillips L.G., Lawrence W.T., et al. The safety and effect of topically applied recombinant basic fibroblast growth factor on the healing of chronic pressure sores. Ann Surg 216 (1992) 402-408
46. Robson M.C., Hill D.P., Smith P.D., et al. Sequential cytokine therapy for pressure sores. Ann Surg 231 (2000) 600-611
47. Payne W.G., Ochs D.E., Meltzer D.D., et al. Long-term outcome study of growth factor-treated pressure sores. Am J Surg 181 (2001) 81-86
48. Richard J.L., Parer-Richard C., Daurers J.P., et al. Effect of topical fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebo-controlled study. Diabetes Care 18 (1995) 64-69
49. Muneuchi G., Suzuki S., Moriue T., et al. Combined treatment using artificial dermis and basic fibroblast growth factor (bFGF) for intractable fingertip ulcers caused by atypical burn injuries. Burns 31 (2005) 514-517
50. Akita S., Akino K., Imaizumi T., et al. A basic fibroblast growth factor improved the quality of skin grafting in burn patients. Burns 31 (2005) 855-858
51. Robson M.C., Phillips T.J., Falanga V., et al. Randomized trial of topically applied repifermin (recombinant human keratinocyte growth factor-2) to accelerate wound healing in venous ulcers. Wound Repair Regen 9 (2001) 347-352
52. Pierce G.F., Mustoe T.A., Altrock B.W., et al. The role of platelet-derived growth factor in wound healing. J Cell Biochem 45 (1991) 319-326
53. Roy H., Bhardwaj S., and Yla-Herttuala S. Biology of vascular endothelial growth factor. FEBS Lett 580 (2006) 2879-2887
54. Bates D.O., and Jones R.O. The role of vascular endothelial growth factor in wound healing. Int J Low Extrem Wounds 2 (2003) 107-120
55. Knighton D.R., Cries K., Fiegel V.D., et al. Stimulation of repair in chronic, nonhealing, cutaneous ulcers using platelet-derived wound healing formula: a preliminary report. Surg Gynecol Obstet 170 (1990) 56-60
56. Atri S.C., Misra J., Bisht D., et al. Use of homologous platelet factors in achieving total healing of recalcitrant skin ulcers. Surg 108 (1990) 508-512
57. Steed D.L., Goslen G.A., Malone J.M., et al. Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. Diabetes Care 15 (1992) 1598-1604
58. Krupski W.C., Reilly L.M., Perez S., et al. A prospective randomized trial of autologous platelet-derived wound healing factors for treatment of chronic nonhealing wounds: A preliminary report. J Vasc Surg 14 (1991) 526-536
59. Senet P., Bon F.-X., Benbunan M., et al. Randomized trial and local biologic effect of autologous platelets used as adjuvant therapy for chronic venous ulcers. J Vasc Surg 38 (2003) 1342-1348
60. Robson M.C., Phillips L.G., Thomason A., et al. Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers. Ann Plast Surg 29 (1992) 193-201
61. Robson M.C., Phillips L.C., Thomasen A., et al. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet 339 (1992) 23-25
62. Mustoe T.A., Cutler N.R., Allman R.M., et al. A phase II study to evaluate recombinant platelet-derived growth factor-BB in the treatment of stage 3 and 4 pressure ulcers. Arch Surg 129 (1994) 213-219
63. Pierce G.F., Tarpley J.E., Allman R.M., et al. Tissue repair processes in healing chronic pressure ulcers treated with recombinant platelet-derived growth factor BB. Am J Pathol 145 (1994) 1399-1410
64. Rees R.S., Robson M.C., Smiell J.M., et al. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study. Wound Repair Regen 7 (1999) 141-147
65. Steed D.L., and the Diabetic Ulcer Study Group. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. J Vasc Surg 21 (1995) 71-81
66. Steed D.L. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers. Plast Reconstr Surg 117 (2006) 143S-149S
67. Margolis D.J., Bartius C., Hoffstad O., et al. Effectiveness of recombinant human platelet-derived growth factor for the treatment of diabetic neuropathic ulcers. Wound Repair Regen 13 (2005) 531-536
68. Shackelford D.P., Fackler E., Hoffman M.K., et al. Use of topical recombinant platelet-derived growth factor BB in abdominal wound separation. Am J Obstet Gynecol 186 (2002) 701-704
69. Hom D.B., and Manivel J.C. Promoting healing with recombinant human platelet growth factor-BB in a previously irradiated problem wound. Laryngoscope 113 (2003) 1566-1571
70. Robson M.C., Hill D.P., Woodske M.E., et al. Wound healing trajectories as predictors of effectiveness of therapeutic agents. Arch Surg 135 3 (2000) 773-777
71. Welsh K.M., Lamit M., and Morhenn V.B. The effect of recombinant human growth hormone on wound healing in normal individuals. J Dermatol Surg Oncol 17 (1991) 942-945
72. Sorhoff H.S., Roszin R.R., Moody J., et al. Role of growth hormone in the response to trauma: I. Metabolic effects following burns. Ann Surg 166 (1967) 739-752
73. Steed D.L., Ricotta J.J., Pentergast J.J., et al. Promotion and acceleration of diabetic ulcer healing by arginine-glycine-aspartic Acid (RGD) peptide matrix. Diabetes Care 18 (1995) 39-46
74. Zhao L.L., Davidson J.F., Wee S.C., et al. Effect of hyperbaric oxygen and growth factors on rabbit ear ischemic ulcers. Arch Surg 129 (1994) 1043-1049
75. Attinger C.E., Janis J.E., Steinberg J., et al. Clinical approach to wounds: debridement and wound bed preparation including the use of dressings and wound-healing adjuvants. Plast Reconstr Surg 7S (2006) 72S-109S